Last updated on February 2018

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)


Brief description of study

The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma (HCC). The primary hypothesis of this study is that overall survival is prolonged in participants who receive pembrolizumab compared to those who receive placebo.

Clinical Study Identifier: NCT03062358

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

The First Affiliated Hospital of Soochow University ( Site 0025)
Suzhou, China
  Connect »